Corcept Therapeutics Inc(CORT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 27 at 4:17 PM ET (Korea 10/28 05:17)
Full metrics table
| Index | - | P/E | 209.29 | EPS (ttm) | 0.42 | Insider Own | 11.4% | Shs Outstand | 107.9M | Perf Week | -24.75% |
| Market Cap | 9.47B | Forward P/E | 21.24 | EPS next Y | 102.67% | Insider Trans | -6.58% | Shs Float | 95.8M | Perf Month | -24.22% |
| Enterprise Value | 9.17B | PEG | 0.21 | EPS next Q | 0.79 | Inst Own | 76.34% | Short Float | 8.97% | Perf Quarter | -5.72% |
| Income | 0.05B | P/S | 11.4 | EPS this Y | 148.24% | Inst Trans | 2.67% | Short Ratio | 6.95 | Perf Half Y | 87.97% |
| Sales | 0.83B | P/B | 13.4 | EPS next 5Y | 102.98% | ROA | 6.41% | Short Interest | 8.59M | Perf YTD | 151.81% |
| Book/sh | 6.54 | P/C | 30.74 | EPS past 3/5Y | -2.15% -0.84% | ROE | 8.08% | 52W High | -30.66% ($126.38) | Perf Year | 20.77% |
| Cash/sh | 2.85 | P/FCF | 88.6 | Sales past 3/5Y | 23.74% 16.56% | ROIC | 7.6% | 52W Low | 205.76% ($28.66) | Perf 3Y | 221.46% |
| Dividend Est. | - | EV/EBITDA | 1040.12 | EPS Y/Y TTM | -59.24% | Gross Margin | 98.3% | Volatility(W/M) | 9.49% 5.45% | Perf 5Y | 398.18% |
| Dividend TTM | - | EV/Sales | 11.04 | Sales Y/Y TTM | 16.02% | Oper. Margin | 0.77% | ATR (14) | 6.15 | Perf 10Y | 1166.33% |
| Dividend Ex-Date | - | Quick Ratio | 2.74 | EPS Q/Q | 23.91% | Profit Margin | 6.52% | RSI (14) | 26.79 | Recom | 1.86 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.83 | Sales Q/Q | 31.74% | SMA20 | -21.69% ($111.9) | Beta | 0.5 | Target Price | $141 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/7/29 | SMA50 | -23.18% ($114.07) | Rel Volume | 0.75 | Prev Close | $87.12 |
| Employees | 730 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | 1381.48% 15.83% | SMA200 | 18.33% ($74.06) | Avg Volume(3M) | 1.24M | Price | $87.63 |
| IPO | 2004/4/14 | Option/Short | Yes/Yes | Trades | 15296 | Volume | 925,414 | Change | 0.58% |
🧬 This is a US commercial-stage biotech company that develops and sells therapeutics based on the mechanism of cortisol (the stress hormone) regulation. It generates revenue and profit by selling treatments for Cushing's syndrome, and is a healthcare stock whose performance is tied to the launch of newly approved therapies and pipeline expansion.
Over the past 1 year, roughly in the middle
31% below its 1-year high.
Traded less than usual. That is 75% of its average volume.
CORT earns at a steady pace
Of every $100 in sales, $0.77 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +148.2% this year.
Tap to view numbers
However, it looks expensive
For a company earning $100 a year, you would pay $20,929. Peers typically go for $3,476. Compared with its own 5-year average, it is 483% pricier now.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
The outlook is positive
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +398.2%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership looks stable
Institutions hold 76.3%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
It ranks #28 of 594 in the industry
Based on market cap of $9B.
KYMR#24 Kymera Therapeutics Inc $10B PER - 
PCVX#25 Vaxcyte Inc $10B PER - 
CAI#26 Caris Life Sciences Inc $10B PER 90.4 
KRYS#27 Krystal Biotech Inc $9B PER 40.2 CORT#28 Corcept Therapeutics Inc $9B PER 209.3 
FAQ
What kind of company is CORT?
CORT belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of CORT?
The market cap of CORT is approximately $9.5B, ranking 959 within its sector.
What is the P/E ratio of CORT?
CORT has a P/E ratio of approximately 209.3x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for CORT?
CORT has recorded a 52-week high of $126.38 and a low of $28.66.
